Skip to main content

Table 2 TACE treatment characteristics and subsequent treatments

From: Conventional transarterial chemoembolization versus drug-eluting bead transarterial chemoembolization for the treatment of hepatocellular carcinoma

  cTACE (n = 174) DEB TACE (n = 76) p
TACE treatment mean ± SD (range) mean ± SD (range)  
TACE sessions per patient (n) 4.00 ± 3.09 (1–18) 2.96 ± 1.79 (1–9) <0.01
Total duration of TACE treatment (days) 217.4 ± 266.1 143.9 ± 171.5 0.01
Subsequent treatment na % na %  
None 105 60.3 48 63.2 0.54
Crossover to other type of TACE      0.41
Yes 27 15.5 15 19.7  
No 147 84.5 61 80.3  
SIRT      0.09
Yes 11 6.3 1 1.3  
No 163 93.7 75 98.7  
Local ablation      0.18
Yes 12 6.9 2 2.6  
No 162 93.1 74 97.4  
Surgery      0.46
Yes 5 2.9 1 1.3  
No 169 97.1 75 98.7  
Sorafenib      0.77
Yes 25 14.4 12 15.8  
No 149 85.6 64 84.2  
Other systemic therapy      0.70
Yes 31 17.8 12 15.8  
No 143 82.2 64 84.2  
Patients receiving ≥2 treatments      1.00
Yes 16 9.2 7 9.2  
No 158 90.8 69 90.8  
  1. TACE transarterial chemoembolization, SD standard deviation, SIRT selective internal radiotherapy
  2. aSome patients received ≥2 subsequent treatments; therefore, the total number of treatments is greater than the total number of patients